A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

There is an unmet need for effective therapies for advanced systemic mastocytosis (advSM). CD30 is expressed on the surface of neoplastic mast cells (MC) in more than 50% of patients with advSM. Brentuximab vedotin (BV) is a CD30-directed antibody-drug conjugate with preclinical evidence supporting...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Gotlib, Jason, Baird, John H., George, Tracy I., Langford, Cheryl, Reyes, Isabel, Abuel, Justin, Perkins, Cecelia, Schroeder, Kurt, Bose, Prithviraj, Verstovsek, Srdan
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693006/
https://ncbi.nlm.nih.gov/pubmed/31350306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000152
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki